Posts Tagged ‘Healthcare’
A new anticoagulant with no risk of bleeding
A UNIGE team, in collaboration with the University of Sydney, has developed a new type of anticoagulant whose action can be rapidly stopped. Anticoagulant treatments are crucial for managing many conditions, such as heart disease, stroke and venous thrombosis. Current options, however, carry an inherent risk of serious bleeding due to trauma or…
Read Morebiped.ai wins the Startup Champions Seed Night 2024
Life sciences shone during the 13th edition of the Startup Champions Seed Night gathering more than 500 people at the Forum Rolex and online! On 25 April 2024, 20 startups pitched their innovative plans to make an impact in the world of modern technology. Co-organised by EPFL (EPFL Alumni and Startup Launchpad) &…
Read MoreOrio Therapeutics Secures CHF 500’000 Pre-Seed Funding
Orio Therapeutics, a biotechnology company at the forefront of protein engineering for regenerative medicine, announced the successful closure of a CHF 500’000 pre-seed funding round. This investment, secured from angel investors, will propel the company’s ambitious goal of revolutionising treatment approaches for patients suffering from debilitating conditions. Orio Therapeutics will utilise the funding…
Read MorePeriVision announces FDA registration for its medical software VisionOne™
PeriVision, proudly announces its recent FDA registration for its first medical software product VisionOne. This significant milestone marks a pivotal moment in PeriVision’s mission to enhance patient care and revolutionise the field of ophthalmology. With VisionOne, ophthalmologists and optometrists can easily configure eye tests on portable VR headsets and subsequently analyse the results…
Read MoreAktiia secures CHF 27 Million
The Neuchâtel-based startup secures CHF 27 Million (USD 30M) in funding from Khosla Ventures and Others. Aktiia mission to revolutionise blood pressure monitoring has gained momentum with the successful closing of our CHF 27 million (USD 30 million) funding round, which was led by Redalpine and included participation from an international investor syndicate…
Read MoreFuture of Health Grant unveils its March 2024 cohort
Startups Resilient SA and Maven Health are among the eight new startups selected by the Future of Health Grant (FoHG) programme. Launched in 2022 by CSS and EPFL Innovation Park to support innovation in digital health, the programme received over 130 applications in its latest call for applications. The eight selected startups will receive…
Read MoreTwo life sciences startups shortlisted for the 31st Prix Strategis
Testmate Health and Seprify are among the eight semi-finalists of this year’s Prix Strategis. Every year for almost 30 years, HEC Espace Entreprise has awarded the Prix Strategis to some of the most promising Swiss start-up with a prize of CHF 50’000. The Strategis Prize is a springboard for young companies with high…
Read MoreAbionic appoints Patrick Pestalozzi as new CEO to propel company into next growth phase
Abionic SA, a Swiss leader in nanofluidic point-of-care diagnostic solutions, announced the appointment of Patrick Pestalozzi as its new CEO, effective 1 April 2024. A former Management Consultant, Silicon Valley executive, and entrepreneur, Patrick brings to Abionic three decades of global experience. In particular, he previously acted as the Vice-President of Global Strategic…
Read More“Bringing meaning back to the healthcare professionals”
Appointed Dean of the Faculty of Medicine at the University of Geneva, Professor Antoine Geissbuhler, is also Director of Teaching and Research at the HUG, and BioAlps President. In an interview to Pulsation Magazine, he has set himself the ambitious goal of meeting the many challenges facing medical education today. What would you…
Read MoreDebiopharm and TransCode Therapeutics Collaborate to Develop Targeted Nucleic Acid Therapeutics for Cancer
TransCode Therapeutics is a RNA oncology company based in the United States committed to more effectively treating cancer using RNA therapeutics. Debiopharm, a privately-owned Swiss-based, global biopharmaceutical company, aims to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. The collaboration will explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in…
Read More